Literature DB >> 16968624

Combination pharmacotherapy for adult ADHD.

Lenard A Adler1, Lisa S Reingold, Melinda S Morrill, Timothy E Wilens.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neuropsychiatric disorders of adulthood. Although clinical guidelines recommend monotherapy with stimulants or atomoxetine, combination pharmacotherapy is a common practice among clinicians. There are four main situations in which combination medications may be necessary: partial response, dose-limiting side effects, associated disorders, and comorbid diagnoses. We present data from two chart reviews that support existing research on combination pharmacotherapy. Adjunct treatment of d-methylphenidate to stimulant medications extended the duration of therapeutic effect. Adjunct treatment of mirtazapine to stimulant medications reduced associated insomnia. These data support previous research that validates the use of combination pharmacotherapy for adults with ADHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968624     DOI: 10.1007/s11920-006-0044-9

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   8.081


  39 in total

1.  Systematic chart review of the pharmacologic treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar disorder.

Authors:  J Biederman; E Mick; J Prince; J Q Bostic; T E Wilens; T Spencer; J Wozniak; S V Faraone
Journal:  J Child Adolesc Psychopharmacol       Date:  1999       Impact factor: 2.576

2.  Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases.

Authors:  J B Prince; T E Wilens; J Biederman; T J Spencer; J R Wozniak
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-05       Impact factor: 8.829

3.  Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology.

Authors:  T E Wilens; T Spencer; J Biederman; J Wozniak; D Connor
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1995-01       Impact factor: 8.829

4.  The effect of methyl phenidate on the sleep cycle in man.

Authors:  F Baekeland
Journal:  Psychopharmacologia       Date:  1966

5.  Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.

Authors:  T Spencer; J Biederman; T Wilens; S Faraone; J Prince; K Gerard; R Doyle; A Parekh; J Kagan; S K Bearman
Journal:  Arch Gen Psychiatry       Date:  2001-08

6.  Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders.

Authors:  Ramon Solhkhah; Timothy E Wilens; Jeanine Daly; Jefferson B Prince; Stephanie L Van Patten; Joseph Biederman
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-10       Impact factor: 2.576

7.  Sleep disturbances in adolescents with symptoms of attention-deficit/hyperactivity disorder.

Authors:  Daniel Stein; Ruth Pat-Horenczyk; Shulamit Blank; Yaron Dagan; Yoram Barak; Thomas P Gumpel
Journal:  J Learn Disabil       Date:  2002 May-Jun

Review 8.  New drugs for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Caroly S Pataki; David T Feinberg; James J McGough
Journal:  Expert Opin Emerg Drugs       Date:  2004-11       Impact factor: 4.191

Review 9.  Management of ADHD in adults.

Authors:  Lenard A Adler; Hong C Chua
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

Review 10.  Novel treatments for attention-deficit/hyperactivity disorder in children.

Authors:  Thomas J Spencer; Joseph Biederman; Timothy E Wilens; Stephen V Faraone
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

View more
  15 in total

Review 1.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 2.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

3.  Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Thomas J Spencer; Michael Greenbaum; Lawrence D Ginsberg; William Rory Murphy
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

4.  An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.

Authors:  Timothy E Wilens; Paul Hammerness; Linsey Utzinger; Mary Schillinger; Anna Georgiopoulous; Robert L Doyle; Marykate Martelon; Kerry Brodziak
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

Review 5.  Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Authors:  Robert L Findling; Shawn A Candler; Azmi F Nasser; Stefan Schwabe; Chungping Yu; Jennie Garcia-Olivares; Welton O'Neal; Jeffrey H Newcorn
Journal:  CNS Drugs       Date:  2021-05-18       Impact factor: 5.749

6.  Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.

Authors:  Vanja Sikirica; M Haim Erder; Jipan Xie; Dendy Macaulay; Melissa Diener; Paul Hodgkins; Eric Q Wu
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

7.  A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).

Authors:  Gerhardt M Pohl; David L Van Brunt; Wenyu Ye; William W Stoops; Joseph A Johnston
Journal:  BMC Health Serv Res       Date:  2009-06-08       Impact factor: 2.655

8.  Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder.

Authors:  Lenard A Adler; David Goodman; Richard Weisler; Mohamed Hamdani; Thomas Roth
Journal:  Behav Brain Funct       Date:  2009-08-03       Impact factor: 3.759

9.  Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.

Authors:  Benno Roesch; Mary E Corcoran; Jennifer Fetterolf; Mary Haffey; Patrick Martin; Peter Preston; Jaideep Purkayastha; Phillip Wang; James Ermer
Journal:  Drugs R D       Date:  2013-06

10.  Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.

Authors:  Benno Roesch; Mary Corcoran; Mary Haffey; Annette Stevenson; Phillip Wang; Jaideep Purkayastha; Patrick Martin; James Ermer
Journal:  Drugs R D       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.